1.	A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: SIM090801, NCT01028729
2.	Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: SHPH-11ZL113, NCT01336192
3.	Treatment of Natural Killer/T Cell Lymphoma-I/II Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011, NCT01501136
4.	Treatment of Natural Killer/T Cell Lymphoma-?/? Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011-2, NCT01501149
5.	Treatment of Peripheral T-cell Lymphoma Phase: Phase IV Type: Treatment Status: Active Age: 14 to 70 Sponsor: Other Protocol IDs: hnslblzlzx2011-3, NCT01664975
6.	Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000470411, FFCD-9902, SANOFI-FFCD-9902, LILLY-FFCD-9902, FFCD-FNCLCC-SFRO-9902, NCT00304135
7.	Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ABC-03 09/0193, NCT00939848
8.	Cisplatin and Radiation Therapy With or Without Gemcitabine Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced Nasopharyngeal Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000657121, SINGAPORE-NCC0901, NCC0901, NCT00997906
9.	Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000675485, PACT-15, 2010-019942-23, SRSI-PACT-15, EU-21040, NCT01150630
10.	Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-DLC-001, NCT01197560
11.	Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-22, 11PAN01, NCT01360853
12.	Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TG4010.14/TIME, 8559, NCT01383148
13.	Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: C-TONG 1103, ML25304, NCT01407822
14.	Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 12154, NCT01438112
15.	Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Approved-not yet active Age: Not specified Sponsor: Other Protocol IDs: TJ20111123, NCT01598584
16.	Phase III Randomized Study of Gemcitabine in Combination With Cisplatin Versus Carboplatin in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-BTOG2-LU3005, EU-20510, NCT00112710
17.	Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: WJTOG0101, NCT00139971
18.	Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEFCAPI O2, NCT00126269
19.	Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: B9E-MC-S062, AB 22/00, NCT00146276
20.	Random Trial for Elderly Patients With NSCLC Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: INJE05-06, NCT00265694
21.	Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: tasmc-05-na-05160-ctil, NCT00295035
22.	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00509, U10CA021115, CDR0000475774, E1505, ECOG-E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
23.	A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HKNPCSG 0502, NCT00370890
24.	Phase III Randomized Study of Chemoimmunotherapy Comprising Gemcitabine Hydrochloride and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
25.	Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EURTAC-SLCG // GECP06/01, EudraCT:2006-003568-73, NCT00446225